Investors looking for stocks in the Medical - Products sector might want to consider either Phibro Animal Health (PAHC) or Boston Scientific (BSX). But which of these two companies is the best option for those looking for undervalued stocks?
BSX is seeing solid international growth, MedSurg market-share gains and surging WATCHMAN sales, though macro and competition remain risks.
After reaching an important support level, Boston Scientific (BSX) could be a good stock pick from a technical perspective. BSX surpassed resistance at the 50-day moving average, suggesting a short-term bullish trend.
Cerity Partners LLC cut its stake in shares of Boston Scientific Corporation (NYSE: BSX) by 5.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,226,179 shares of the medical equipment provider's stock after selling 75,325 shares during the period.
The latest trading day saw Boston Scientific (BSX) settling at $97.79, representing a +2.42% change from its previous close.
Altfest L J and Co. Inc. lowered its holdings in Boston Scientific Corporation (NYSE: BSX) by 31.7% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,562 shares of the medical equipment provider's stock after selling 5,840 shares during the
Brookwood Investment Group LLC increased its position in Boston Scientific Corporation (NYSE: BSX) by 119.9% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 13,092 shares of the medical equipment provider's stock after purchasing an additional 7,138 shares during the quarter. Brookwood
MARLBOROUGH, Mass., Jan. 2, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in the 44th Annual J.P.
Generali Asset Management SPA SGR boosted its position in shares of Boston Scientific Corporation (NYSE: BSX) by 7.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 89,738 shares of the medical equipment provider's stock after acquiring an additional 6,433 shares
Bank Pictet and Cie Europe AG trimmed its stake in Boston Scientific Corporation (NYSE: BSX) by 4.1% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 157,936 shares of the medical equipment provider's stock after selling 6,718 shares during the
BSX's $50B cardiovascular business aims to outpace market growth across EP, WATCHMAN, ICTx and more.
Calamos Advisors LLC reduced its position in shares of Boston Scientific Corporation (NYSE: BSX) by 21.5% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 894,430 shares of the medical equipment provider's stock after selling 244,349
Calamos Wealth Management LLC boosted its stake in Boston Scientific Corporation (NYSE: BSX) by 52.3% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 155,038 shares of the medical equipment provider's stock after buying an additional 53,252 shares during the period. Calamos Wealth
Boston Scientific edges out Resmed as WATCHMAN momentum, EP gains and acquisitions fuel stronger recent price performance in a growing medical device market.
Sowell Financial Services LLC cut its position in Boston Scientific Corporation (NYSE: BSX) by 51.1% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 27,546 shares of the medical equipment provider's stock after selling 28,806 shares during the quarter. Sowell Financial Services
Boston Scientific is recommended as a buy with a $109 target price, implying 14% upside, driven by robust demand and niche leadership. BSX outpaces market growth through focused M&A, strong execution in Cardiovascular and MedSurg segments, and sustained double-digit revenue and EPS expansion. Recent Q3 results exceeded expectations, prompting management to raise FY25 guidance; high demand for Watchman and FARAPULSE are key growth drivers.
Investors interested in Medical - Products stocks are likely familiar with Phibro Animal Health (PAHC) and Boston Scientific (BSX). But which of these two stocks presents investors with the better value opportunity right now?
BSX's Endoscopy unit targets an $8B market, spanning pancreaticobiliary, surgery and obesity, with plans to outgrow the market.
This basket of 64 medical device stocks could raise its dividend for decades.
Exchange Traded Concepts LLC increased its holdings in shares of Boston Scientific Corporation (NYSE: BSX) by 54.4% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 64,663 shares of the medical equipment provider's stock after buying an additional 22,791